Prostate Cancer Survivorship in Veterans
Many of these survivors have experienced a range of physical and psychological effects, including urinary incontinence, erectile dysfunction, posttraumatic stress disorder, and treatment regret.
In this panel ReCAP, produced in partnership with the Association of VA Hematology/Oncology (AVAHO), Drs Michael Goodman, Michael Chang, and Jeffrey Jones discuss how healthcare professionals can address the needs and concerns of these patients.
The panelists begin by reporting that veterans are disproportionately diagnosed with prostate cancer earlier than men in the general population, and typically they have more aggressive cancers.
The doctors next examine treatment options for these men and how related effects of surgery, radiation, and androgen deprivation therapy affect those decisions.
They also discuss the psychosocial effects of prostate cancer, including the risk for embarrassment from incontinence and erectile dysfunction as well as the psychological burden relating to risk for recurrence.
Finally, the experts emphasize the importance of multidisciplinary care and shared decision-making. They outline how urologists, oncologists, and radiation oncologists need to work together with their patients to ensure the physical and psychological needs of veteran prostate cancer survivors are met.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Human Osteoblasts Market to Reach US$ 87.1 Million by 2033
The market is currently experiencing robust growth, fueled by a post-pandemic surge in orthopedic surgeries and significant investment in regenerative medicine. Innovations in 3D bioprinting and smart scaffolds are creating new therapeutic possibilities for bone repair. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the forecast period 2025–2033. The future potential of the human osteoblasts market lies in the convergence of artificial intelligence with advanced biomanufacturing. AI-powered platforms are now capable of analyzing genomic data from 1000s of individuals to predict osteoblast response to new drug compounds, drastically reducing discovery timelines. This synergy is enabling the creation of patient-specific 3D-bioprinted bone grafts. As of 2025, researchers are successfully embedding patient-derived osteoblasts into custom scaffolds with 95% cell viability post-printing. These constructs are being tested in preclinical models for craniofacial reconstruction and spinal fusion, promising a new era of personalized regenerative medicine. Demand for highly characterized osteoblasts for these applications is projected to soar. Download Sample Pages: Another significant growth frontier of the human osteoblasts market is the application of osteoblast research to counteract microgravity-induced bone loss in astronauts. With 3 new long-duration space missions planned by international agencies before 2028, research into osteoblast function in simulated microgravity is intensifying. Furthermore, the veterinary orthopedics market represents a substantial, untapped opportunity. In 2024, an estimated 1.2 million companion animals in the U.S. alone underwent procedures for fractures or degenerative joint diseases. The development of canine and equine osteoblast cell lines for testing new veterinary implants and cell-based therapies is an emerging field that could create an entirely new vertical within the broader market. Key Findings in Human Osteoblasts Market Market Forecast (2033) US$ 87.1 million CAGR 6.8% Top Drivers Rising prevalence of osteoporosis and degenerative bone diseases globally. Technological advancements in cell-based therapies and tissue engineering. Increasing geriatric population driving demand for orthopedic surgical procedures. Top Trends Shift towards personalized medicine using patient-derived osteoblast cultures. Development of 3D bioprinting for creating patient-specific bone grafts. Growing adoption of minimally invasive bone regeneration surgical techniques. Top Challenges Expensive cell-based therapies and procedures. Stringent and complex regulatory approval pathways for new biologics. Top 12 Key Players Strategically Dominate the Evolving Global Human Osteoblasts Market The competitive environment is both concentrated and highly specialized. Analysis in 2024 consistently identifies 12 key players shaping the industry. These include Sigma-Aldrich, Athersys Inc., Cerapedics Inc., CryoLife, Inc., and Cytori Therapeutics Inc. Other notable companies are USA Stem Cell Inc., Vericel Corporation, Wright Medical Group N.V, Biocomposites, BD, Zimmer Biomet, and PromoCell. In the crucial U.S. orthopedic biomaterials sector, a key application area, 3 major competitors—Medtronic, DePuy Synthes, and Stryker—were noted as dominant forces in 2024. Suppliers offer highly specific product lines to meet diverse research needs. As of 2025, PromoCell provides 4 primary product categories related to osteoblasts, including cells and specialized growth media. Similarly, Innoprot offers 2 distinct types of primary human osteoblasts as of 2024 Human Calvarial and Human Femoral Osteoblasts in the human osteoblasts market. InSCREENex provides 1 specific immortalized human osteoblast cell line, CI-huOB. Product quality and performance are paramount. Lonza guarantees 10 population doublings for its Clonetics™ Normal Human Osteoblasts, ensuring robust expansion for 2024 research. Innoprot's immortalized cells demonstrate a growth potential of over 30+ passages, a significant advantage. Recent Product and Technology Launches Signal Rapid Advancement Within the Market Innovation remains a cornerstone of human osteoblasts market growth, with companies actively launching advanced products. On April 15, 2024, CryoLife, Inc. introduced 1 new osteoblast culture system designed to enhance cell viability. Zimmer Biomet followed suit in February 2024, launching 1 new bioreactor system for osteoblast cultivation with improved scalability. Innovation extends to cell preservation. In 2024, PromoCell released 1 new protein- and animal component-free cryopreservation medium, Cryo-SFM Plus, featuring advanced antioxidant technology. Intellectual property is also a key competitive tool. Bone Solutions Inc. was awarded 5 new patents in fiscal year 2025 for its Mg OSTEOCRETE technology, a bone substitute that stimulates osteoblast activity. Practical usability is crucial for clinical adoption. Bone Solutions' Mg OSTEOCRETE boasts a preparation time of just 30 seconds, a significant handling benefit for 2025 applications. To support adjacent research fields, PromoCell also launched 1 new Cancer Media Toolbox in 2024 to facilitate the establishment of primary cancer cell lines and complex 3D tumor models. Active Clinical Trials for Osteoblast-Related Therapies Underpin Future Market Expansion The clinical development pipeline is a strong indicator of future commercial opportunities. In February 2024, Biocomposites initiated 2 Phase 2 clinical trials for its STIMULAN VG® bone graft substitute. These trials will assess efficacy in treating diabetic foot osteomyelitis and stage 4 pressure ulcers. Osteosarcoma research, a critical area for the human osteoblasts market, is also advancing. In 2024, the Osteosarcoma Institute (OSI) sponsored 1 Phase 2 clinical trial in Spain for OMO-103, a promising MYC inhibitor. A remarkable 25 months was the fast-tracked timeline to launch the OMO-103 trial, showcasing increased efficiency in clinical development. In the United States, a 2024 study was published on 1 FDA/IRB-approved GMP-manufactured stem cell product, PSC-01, for knee osteoarthritis. The study showed that a single treatment provided pain reduction and increased function for 2.5 years. Research methodologies are also being refined. A 2024 clinical trial enrolled 30 patients to analyze the effects of lasers on alveolar bone preservation. A Phase 1 trial protocol published in 2024 detailed a 3+3 dose escalation method for a study using human umbilical cord-derived osteoblasts for femoral head osteonecrosis. Favorable Regulatory Approvals in 2024 Create a Promising Outlook for Therapies The regulatory climate for cell and gene therapies in the human osteoblasts market became increasingly favorable in 2024. The FDA approved 7 new cell and gene therapy products Amtagvi, Aucatzyl, Beqvez, Kebilidi, Ryoncil, Symvess, and Tecelra. The pace of approvals is accelerating, with 3 of these therapies gaining approval in early 2024 alone. On December 19, 2024, the FDA approved 1 mesenchymal stem cell product, Ryoncil from Mesoblast. Another landmark approval was granted on November 13, 2024, for 1 gene therapy for AADC deficiency, Kebilidi from PTC Therapeutics. On November 8, 2024, the FDA approved 1 CD19-directed T-cell immunotherapy, obecabtagene autoleucel (Aucatzyl), from Autolus Inc. The recommended dose for Aucatzyl is 410x10^6 CAR-positive viable T-cells. StemCyte received approval for 1 allogeneic hematopoietic stem cell therapy, Regenecyte, on November 26, 2024. Patent activity, a precursor to commercialization, is also strong. Innovators at the University of Pittsburgh were issued 5 patents in August 2024, while University of Minnesota researchers secured 111 US patents in 2024 for various health science discoveries. Significant Funding and Strategic Grants Accelerate Osteoblast-Focused Research and Development Robust financial investment is fueling the engine of scientific discovery across the global human osteoblasts market. The Osteosarcoma Institute (OSI) awarded $1,100,000 to 3 groundbreaking osteosarcoma research projects during its 2023–2024 grant cycle. One of these grants provided $500,000 in funding to Dr. David Lyden's team for a project focused on metastasis. The impact of such funding is often magnified. Building on an initial OSI grant, Baylor College of Medicine secured $4,500,000 in additional funding in 2024 to advance CAR-T therapy research. International collaborations are also being funded. In October 2024, one US–Israel Binational Science Foundation grant was awarded to a team including University of Vermont Cancer Center members to study osteosarcoma epigenetics. Wherein, government funding remains critical. In August 2024, Medical College of Georgia scientists received a five-year grant of $2,400,000 from the National Institute on Aging to study how stress hormones signal the skeleton. Philanthropic efforts are also significant, with over $4,600,000 raised from more than 1,000 donations in 2024 to support the OSI's vital mission. Diverse and Critical Applications Are Driving Widespread Adoption Across Multiple Fields The utility of human osteoblasts market extends across a wide spectrum of research and clinical applications. The dynamic interplay between 2 key cell types, osteoblasts and osteoclasts, is central to bone health, driving research into osteoporosis. In the laboratory, standardized protocols are essential. Human osteoblasts from PromoCell require approximately 3 weeks to show detectable mineralization in culture. Advanced 3D modeling is becoming a standard research tool. InSCREENex's immortalized human osteoblasts can form 3D "mini-bones" when cultured under specific conditions. Suppliers like PromoCell target 3 key application areas cell expansion, culture initiation, and differentiation. A 2024 study highlighted the use of 1 new 3D model based on human fetal osteoblasts to study osteocyte commitment. The clinical relevance is clear. The classic period for new bone formation after a tooth extraction, a process driven by osteoblasts, is 6-10 weeks. A 2025 study analyzed ion release from 3D printed scaffolds at 3 days, 7 days, and 15 days, key time points for osteoblast interaction. Quality Guarantees and Emerging Technologies Redefine the Global Human Osteoblasts Market The reliability of research outcomes depends on the quality of the underlying cell products. Suppliers in the market provide stringent quality guarantees. PromoCell guarantees >500,000 viable cells per cryovial after thawing. Innoprot similarly ensures >500,000 viable cells in each vial, cryopreserved at passage one, while Lonza guarantees ≥500,000 viable cells per ampule. For immortalized lines, Innoprot provides >1,000,000 viable cells per vial, and InSCREENex includes >0.5 million viable cells per vial. Longevity in culture is also specified. Innoprot guarantees 15 population doublings for its primary osteoblasts post-delivery. PromoCell recommends a split ratio of 1:3 to 1:6 for its primary cells. To support targeted research, PromoCell holds >100 HLA-typed cell donors in stock as of 2024, offering 4-digit high-resolution typing. The InSCREENex cell line was derived from a 63-year-old female donor. Concurrently, emerging technologies are creating new opportunities for the human osteoblasts market. Three key trends noted in the 2024 orthopedic biomaterials market are biodegradable materials, 3D printing, and nanotechnology. A September 2024 paper detailed 1 study using collagen-based 3D printed scaffolds to investigate osteoblast activity. A May 2024 publication described 1 new 3D in-vitro model using human fetal osteoblasts. A 2025 study utilized 2 cell lines to test 3D printed composite samples, using standards prepared from 1,000 mg/L stock solutions and a plating density of 10,000 cells/well for viability tests. Customize the Data Scope to Match Your Objectives: Strategic Alliances and Focused Regional Developments Indicate Strong Global Market Growth Corporate strategies and regional activities in 2024 and 2025 underscore a commitment to global expansion of the human osteoblasts market. On March 10, 2024, 1 major collaboration was announced between Athersys Inc. and Cerapedics Inc. to develop a novel osteoblast-based therapy. Service providers are also expanding. In 2024, Thermo Fisher launched its "Accelerator™ Drug Development" solutions, offering 360-degree support to biotech companies. Licensing agreements are expanding market access for key biologics. Bio-Thera Solutions entered into 1 exclusive licensing agreement on December 24, 2024, for its ustekinumab biosimilar. On the same day, GlycoNex announced 1 licensing agreement for its denosumab biosimilar, a therapy for bone loss. Regional market activities are intensifying. In 2024, 1 pivotal Phase 2 trial for osteosarcoma was opened in Barcelona, Spain. Stryker expanded with 1 new testing facility in India in February 2024. In May 2024, Sanofi announced 1 new partnership with OpenAI to accelerate R&D. The North American market saw the FDA grant 1 US approval to Pfizer's Beqvez on April 25, 2024. Europe showed activity with 1 approval by the UK's MHRA on January 15, 2025. The Asia-Pacific region is also growing, evidenced by 1 approval in Japan on January 7, 2025, for Biocon's ustekinumab. Global Human Osteoblasts Market Major Players: Athelas Bionova Scientific Cell Signaling Technology Corning EMD Millipore Invitrogen Lonza Merck Group NantKwest Promega R and D Systems ReproCELL Sigma-Aldrich Stemcell Technologies Thermo Fisher Scientific Other Prominent Players Key Market Segmentation: By Product Human Cell Culture Osteoblast Cell Lines By Application Traumatic Injuries Road Accidents Regeneration Surgeries Orthopedics Musculoskeletal and Spine Neurology By End user Hospitals Specialty Clinics Ambulatory Surgical Centers By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Bluesight introduces ShortageCheck to manage drug inventories in hospitals
Hospital intelligence solutions provider Bluesight has launched ShortageCheck technology designed to assist health systems and hospitals in tracking, forecasting and managing drug inventories. ShortageCheck integrates real-time inventory data, predictive analytics, and collaborative planning tools into a comprehensive platform. This innovation is poised to ensure that caregivers and patients have uninterrupted access to essential medications. Monitoring over 20 real-time market signals, encompassing demand spikes and fulfilment delays, ShortageCheck provides coverage across more than 2,500 acute care facilities across the US. It identifies early warning signs of drug shortages, offering up to a 90-day lead time, with an average of 42 days, allowing healthcare institutions to prepare and adapt their inventory management strategies. By assessing levels of inventory, usage rates along with days-on-hand, the platform offers in-depth insights into the potential impact of each shortage. This enables organisations to evaluate risk, prioritise responses and leverage ShortageCheck's communication tools for cross-team coordination and planning. Bluesight CEO and co-founder Kevin MacDonald said: 'Shortage management has been one of, if not the most critical, pain point for our customers over the last six years. When drug shortages hit without warning, it forces teams to scramble for alternatives, and patient care ultimately suffers. 'With improving health system operations as our top priority, the launch of ShortageCheck marks a significant milestone in ensuring customers have the solutions needed to get ahead of shortages before they hit, preserving labour hours and costs during a time when drug costs are rising, staff shortages persist, and medicare reimbursement changes are on the horizon.' ShortageCheck is part of the hospital intelligence solutions suite of Bluesight, which includes CostCheck, KitCheck, 340BCheck, ControlCheck and PrivacyPro. These tools collectively offer hospitals the capability to restock inventory quicker, reduce drug expenditure, streamline audit preparations, pinpoint drug diversion more effectively, and save time in protecting patient privacy. This January, Bluesight expanded its capabilities by acquiring Protenus, a healthcare compliance analytics platform provider. "Bluesight introduces ShortageCheck to manage drug inventories in hospitals" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Wisdom, the AI-Powered Dental Revenue Cycle Management Platform, Raises $28M to Accelerate Product Innovation and Capitalize on Rapid Growth
SAN FRANCISCO, August 20, 2025--(BUSINESS WIRE)--AI in revenue cycle management has become top of mind across the healthcare industry, but when it comes to the dental market, dentists are lacking the modern tools used by their medical counterparts. That's the problem that AI-powered dental RCM platform, Wisdom, is on a mission to solve. The company announced today the successful completion of its $21M Series A capital raise led by Permanent Capital Ventures (PCV), a venture capital firm that partners with founders to build go-to-market engines for enterprise scale. Aquiline, a private investment firm specializing in financial services and technology, joined the round, alongside existing investor and Co-Founder, Juxtapose, a leading creation-oriented investment firm. Juxtapose followed their recent $7M Seed investment, reaffirming the firm's commitment to Wisdom's continued growth and innovation. This funding brings Wisdom's total capital raised to $28M since its founding in 2023. The overwhelming majority of independent practices and small dental groups in America struggle with the administrative burden of running a profitable business, leaving over $20 billion of earned revenue uncollected despite spending billions of dollars on salaries for in-house revenue management. Wisdom, which has already collected hundreds of millions of dollars for its clients and saved them up to 50% of collection costs, takes a highly differentiated approach to administrative workflows by bringing AI agents and human experts together to maximize revenue collections, predictability, transparency and patient satisfaction, thereby freeing dentists and their staff to focus on delivering outstanding patient care. Since its inception, Wisdom has rapidly expanded by combining advanced, proprietary AI-driven technology with US-based billing experts. This unique approach has propelled Wisdom to achieve exceptional client satisfaction, underscored by a consistently high Net Promoter Score of 73 and strong organic growth. Over 50% of Wisdom's signed deals still come through referrals. Wisdom was awarded Top Dental Billing Company by Healthcare Business Review earlier this year and was named a 2025 Dental Innovator Award winner by DentalIQ for its AI-assisted dental billing service. Wisdom is led by CEO Stoyan Kenderov, an accomplished technologist, product leader and executive with over 25 years of success building new products and transforming organizations into customer-obsessed teams that drive growth and profitability, most recently as COO of business payments platform Plastiq. Prior to his time at Plastiq, Stoyan held senior leadership roles at LendingClub, Intuit, Quicken, and many other international technology companies. Stoyan is joined by Wisdom Co-Founder and Chief Dental Billing Officer Ashley Bond, who previously founded and led the award-winning nationwide billing service, Bond Dental Billing. "We are thrilled to partner with PCV and Aquiline as we continue our mission to transform dental billing and revenue management," said Kenderov. "Their proactive approach and expertise in building scalable enterprises align perfectly with our vision to significantly enhance financial outcomes and operational efficiency for dental practices." PCV's investment in Wisdom reflects the firm's strategy of supporting innovative startups poised for transformational growth. "Wisdom has created an impressive track record by uniquely integrating AI technologies with deep industry expertise," said Mike Gamson, Co-Founder and Managing Partner at Permanent Capital Ventures. "We see immense potential in their ability to scale and redefine revenue management solutions in the dental sector and beyond." Aquiline has a history of building scaled revenue cycle management businesses, and this investment in Wisdom marks the firm's second investment supporting the dental industry. "While we continue to see significant innovation across dental, the market is filled with point solutions and generally lacks modern, end-to-end platforms, especially across the rev cycle process," said Dante La Ruffa, Partner at Aquiline. "We believe that Stoyan and his team are reimagining the future of dentistry, starting with the key pain points that have historically inhibited dentists from maximizing their time with patients." This funding will enable Wisdom to further enhance its technology platform, accelerate market expansion, and continue building out its exceptional team to better serve dental offices of all sizes - from private practices to multi-location dental groups across the country. "The opportunity to use technology to help dentists build and run their businesses more effectively is immense. Stoyan and his team have moved quickly but thoughtfully to build a solution which really moves the needle for dentists while preserving the value of human expertise," said Andy Stein, Partner at Juxtapose. For more information about Wisdom and its innovative dental billing solutions, please visit About Juxtapose Juxtapose is a creation-oriented investment firm building and funding industry-defining technology companies. Juxtapose's concept development and investment process is focused on multi-decade opportunities in complex industries that leverage the team's expertise in software and technology, human-centered design, commercial strategy, executive talent assessment, and private capital markets. Juxtapose has built and led the financing of companies across software, healthcare, and tech-enabled services that have raised over $1B of external, follow-on private capital. Founded in 2016, Juxtapose now has over $1B AUM. About Permanent Capital Ventures Permanent Capital Ventures is an expansion stage venture capital firm that partners with extraordinary founders building AI application businesses. We lean in with unique go-to-market expertise in the moments after product-market fit has been established to help unlock the path to enterprise scale. About Aquiline Aquiline Capital Partners LP ("Aquiline") is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management across the firm's three strategies in private equity, venture, and credit. Additional information is available on the firm's website: Aquiline Capital Partners LP ("Aquiline") is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management and has deployed approximately $7.4 billion of capital across the firm's three strategies in private equity, venture, and credit. View source version on Contacts Aquiline media contact:Charlie Cumiskey, Apella Advisors+44 (0)7958 964446, aquiline@ Wisdom Media contact:Brian Becker, Wisdombrian@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
